Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taiho: Abraxan for Breast Cancer
August 2, 2010
- Pfizer to Begin PIII Trial for Selara for Chronic Heart Failure
August 2, 2010
- AZ: Pulmicort Inhaler for Asthma in Children
August 2, 2010
- RaQualia Begins PI Trial for APA in the US
August 2, 2010
- All Candidates from Nichiiren Fail to Obtain Seat in Upper House
July 26, 2010
- Iressa Doubles PFS in Japanese NSCLC Patients with Mutated EGFR
July 26, 2010
- Parliamentary Secretary for Health Shinya Adachi Reelected
July 26, 2010
- Kobayashi to Develop More Class 1 OTC Drugs
July 26, 2010
- Dr Fujii Regains Seat in Upper House
July 26, 2010
- JPA to Renew Its Efforts to Increase Members' Awareness of New OTC Drug Sales System
July 26, 2010
- Standardize Interpretation of 1980 Notification: Chuikyo
July 26, 2010
- Erbitux Associated with Fewer Severe Infusion Reactions in Japan
July 26, 2010
- Industry Criticized Again at Chuikyo Meeting
July 26, 2010
- Test for Predicting Efficacy of IFN Recommended for Approval as Advanced Technology
July 26, 2010
- Use of New Drugs Increasing in Cancer Therapy: CareNet
July 26, 2010
- Most Member Pharmacies Have Correctly Understood Significance of Premium: NPhA
July 26, 2010
- Nippon Chemiphar Aims at Sales of ¥30.0 Bil. with Generics in FY2012
July 26, 2010
- Interest Shown in Development of 3 More Unapproved Drugs
July 26, 2010
- Drug Market in Japan to Grow 3-6% in 2010-2014: IMS Japan
July 26, 2010
- Takeda Confident about Actos Data
July 26, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…